|
gptkbp:instanceOf
|
gptkb:drug
antineoplastic agent
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:approvedBy
|
gptkb:US_FDA
|
|
gptkbp:ATCCode
|
P01CX05
|
|
gptkbp:bioavailability
|
>80%
|
|
gptkbp:CASNumber
|
58066-85-6
|
|
gptkbp:category
|
World Health Organization essential medicine
|
|
gptkbp:chemicalFormula
|
C21H46NO4P
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:developedBy
|
antineoplastic agent
|
|
gptkbp:discoveredBy
|
gptkb:Asta_Medica
|
|
gptkbp:drugClass
|
alkylphosphocholines
|
|
gptkbp:eliminationHalfLife
|
150-200 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:first_approved_in
|
gptkb:India
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Miltefosine
|
|
gptkbp:indication
|
gptkb:mucocutaneous_leishmaniasis
gptkb:visceral_leishmaniasis
leishmaniasis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
disrupts cell membrane of protozoa
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:molecularWeight
|
407.6 g/mol
|
|
gptkbp:origin
|
gptkb:Germany
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
teratogenicity
|
|
gptkbp:synonym
|
gptkb:Impavido
gptkb:hexadecylphosphocholine
|
|
gptkbp:usedFor
|
leishmaniasis
amoebic meningoencephalitis
primary amoebic meningoencephalitis
|
|
gptkbp:bfsParent
|
gptkb:Leishmania_parasites
|
|
gptkbp:bfsLayer
|
7
|